Bio-Techne to Be Acquired by Merck KGaA
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Bio-Techne ( (TECH) ) just unveiled an update.
On June 25, 2026, Bio-Techne agreed to be acquired by Merck KGaA, Darmstadt, Germany, in an all-cash merger valuing each Bio-Techne share at $73, with Bio-Techne to survive as a wholly owned subsidiary through a merger with a Merck-controlled vehicle. The board unanimously deemed the transaction in the best interests of shareholders, set it for a shareholder vote and put standard covenants in place requiring the company to operate in the ordinary course pending closing.
The deal includes detailed cash treatment of stock options, restricted stock units, performance units and restricted stock, conversion of unvested awards into cash-based instruments, and termination of Bio-Techne’s equity and employee stock purchase plans before closing. Completion is subject to shareholder approval, global antitrust and investment screening clearances, and customary conditions, with a long-stop date of March 25, 2027 and potential extensions, alongside a dual termination-fee structure that imposes a $230.5 million break fee on Bio-Techne in certain competing bid scenarios and a $576.1 million fee on Merck KGaA if regulatory hurdles ultimately block the transaction.
The most recent analyst rating on (TECH) stock is a Hold
with a $73.00 price target.
To see the full list of analyst forecasts on Bio-Techne stock,
see the TECH Stock Forecast page.
Spark’s Take on TECH Stock
According to Spark, TipRanks’ AI Analyst, TECH is a Outperform.
The score is driven primarily by strong cash generation and a solid, low-leverage balance sheet, which help cushion a weaker TTM growth/profitability period. A definitive all-cash acquisition agreement at a premium is a meaningful positive. Offsetting these are a stretched valuation (very high P/E) and technicals that look extended, alongside management’s near-term expectation for roughly flat organic growth.
To see Spark’s full report on TECH stock,
click here.
More about Bio-Techne
Bio-Techne Corporation is a Minnesota-based life sciences company that provides biotechnology products and solutions, including research reagents and diagnostic tools, to pharmaceutical, academic and clinical customers. The company operates in a highly regulated global market and focuses on supporting drug discovery, diagnostics and biomedical research applications across multiple geographies.
Average Trading Volume: 3,542,064
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.07B
Find detailed analytics on TECH stock on TipRanks’ Stock Analysis page.
